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Abstract Anti-neutrophil cytoplasmic antibody (ANCA)-
positive vasculitis—the term recently applied to Wegener's
granulomatosis—is a rare multi-system inflammation char-
acterized by necrotizing granulomas and vasculitis. We
investigated the ocular manifestations of this disease in a
group of patients drawn from five inflammatory eye disease
clinics across the United States. Of 8,562 persons with
ocular inflammation, 59 individuals were diagnosed with
ANCA-positive vasculitis; 35 males and 21 females, aged 16
to 96 years, were included in this study. Ocular diagnoses
were scleritis (75.0%), uveitis (17.9%), and other ocular
inflammatory conditions (33.9%) including peripheral ulcer-
ative keratitis and orbital pseudotumor. Mean duration of
ocular disease was 4.6 years. Oral corticosteroids and other
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and 78.5% of patients, respectively. Over time, patients with
ANCA-positive vasculitis experienced 2.75-fold higher
mortality than other patients with inflammatory eye disease.
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Introduction
Anti-neutrophil cytoplasmic antibody (ANCA)-positive
vasculitis—a term that is favored to designate the disease
otherwise known as Wegener's granulomatosis [1]—is a
rare multi-system disease that is classically described as
consisting of necrotizing granulomas and vasculitis of the
respiratory tract, generalized small vessel vasculitis, and a
focal necrotizing glomerulonephritis [2]. In addition to
renal and respiratory tract involvement, patients may have
cutaneous, rheumatologic, neurologic, and ocular inflam-
mation. Cases in which renal manifestations are absent are
considered to represent a “limited” form of the disease [2].
Although the pathogenesis of ANCA-positive vasculitis is
incompletely understood, it is thought to be of complex
mechanism involving aberrant humoral and cell-mediated
immune responses [3]. More than 90% of patients with
active disease test positively for the proteinase 3 anti-
neutrophil cytoplasmic antibody (Pr3 ANCA). The precise
role of ANCAs in the pathogenesis of the disease has not
been defined, but they are believed to mediate the
granulomatous inflammation and vascular destruction that
are hallmarks of the disease [3].
The prevalence of ANCA-positive vasculitis in the
United States is reported to be 3.0 cases per 100,000
population [4]. Various studies conducted in the United
Kingdom have estimated the annual incidence to be 0.5 to
8.5 cases per million [2]. A large prospective study
conducted by investigators at the National Institute of
Allergy and Infectious Diseases (NIAID) did not demon-
strate a gender predilection and suggested that the disease
was more prevalent in whites than in other races [5].
Mortality and morbidity of ANCA-positive vasculitis are
substantial. In the study performed at NIAID, the disease or
complications arising from therapy led to death in 13% of
158 patients over 1,229 patient-years of follow-up [5]. In
the same study, 86% of patients suffered irreversible
disease-related morbidity, and 42% of patients experienced
morbidity related to adverse effects of treatment.
Inflammatory eye disease is described in 50% to 60% of
patients with ANCA-positive vasculitis, and for 8% to 16%
of patients, it is an initial manifestation [6]. Case reports
and studies from single centers describe a diverse range of
ocular involvements, from eye wall inflammations, includ-
ing conjunctivitis and scleritis, to orbital masses; the most
commonly reported ophthalmic manifestations have been
orbital disease and scleritis [5–16]. To provide a more
complete description of the ocular disease in patients with
ANCA-positive vasculitis, we investigated clinical aspects
of the disease in a cohort of patients managed at five
tertiary-referral inflammatory eye disease clinics located
within the United States.
Methods
The Systemic Immunosuppressive Therapy for Eye Dis-
eases (SITE) cohort is a group of individuals with non-
infectious inflammatory eye disease who have been
managed at five North American inflammatory eye disease
subspecialty clinics between 1978 and 2007 [17]. The
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j ocul biol dis inform (2010) 3:12–19 13cohort was assembled primarily to evaluate the risk of
mortality associated with the use of systemic immunosup-
pressive drugs in this patient population [18]. Demograph-
ic, clinical, and treatment-related variables associated with
each visit made by each patient to a study center have been
collected retrospectively by standardized chart review. For
four centers, all eligible patients were enrolled in the study.
At the fifth center, approximately 40% of eligible patients
were enrolled; sampling was random, with oversampling of
patients most likely to be treated with systemic immuno-
suppression and patients presenting early in the observation
period. Data collection followed the Declaration of Helsinki
with approval from the institutional review boards of each
institution.
The size and breadth of the SITE cohort provided an
excellent opportunity for investigation of specific forms of
inflammatory eye disease. In this study, the SITE database
was mined to obtain data relating to all patients registered
with the diagnosis of ANCA-positive vasculitis.
After identification of patients, demographic character-
istics were collected, including gender, race, age at
diagnosis, and duration of disease. The database was
further scrutinized for disease-specific variables. In partic-
ular, the database was queried to calculate the proportion of
patients with specific ocular diagnoses (i.e., anterior uveitis,
intermediate uveitis, posterior uveitis and panuveitis,
scleritis, and “other”), who also had a diagnosis of
ANCA-positive vasculitis. The construction of the database
allowed for documentation of more than one form of
inflammatory eye disease when applicable. Subtypes and
patterns of disease were collated for patients with scleritis.
Scleritis was classified by subtype, as described by Watson
and Hayreh, [19] and subtypes were defined according to
laterality, distribution of the inflammation, and temporal
course of the disease, as applicable.
Limited data relating to the management of patients with
inflammatory eye disease according to systemic inflamma-
tory diagnosis were reported in the original SITE cohort
study [17]. In the present study, all relevant systemic
medications administered during the study period and all
surgical procedures were tabulated for patients with
ANCA-positive vasculitis. Systemic medications included
oral corticosteroids and other systemic immunosuppressive
agents (i.e., methotrexate, azathioprine, mycophenolate
mofetil, leflunomide, dapsone, cyclosporine, tacrolimus,
sirolimus, cyclophosphamide, chlorambucil, and biologic
agents). Surgical interventions were categorized as: cataract
surgery, glaucoma surgery, and “other ocular surgery”.
Among the subset of patients seen on or before
December 31, 2005, who were residents of the United
States (i.e., maintaining an address within the United
States), data on the risk of mortality through the end of
2005 were available. In the original SITE cohort study,
ANCA-positive vasculitis was identified as a non-treatment
factor that was associated with an increased risk of death in
within cohort comparisons [17]. The risk of mortality for
patients with ANCA-positive vasculitis was calculated with
respect to patients free of that diagnosis using survival
analysis. Cox multiple regression was performed to adjust
for confounding by demographic and clinical character-
istics, including age, sex, race, smoking status, primary site
of ocular inflammation, Charlson Index score [20], and the
presence of systemic immune-mediated diseases (i.e.,
reactive arthritis, psoriatic arthritis, ankylosing spondylitis,
Behçet's disease, polyarteritis nodosa, giant cell arteritis,
other forms of arteritis, systemic lupus erythematosus,
scleroderma, Sjögren's syndrome, dermatomyositis, poly-
myositis, juvenile idiopathic arthritis, relapsing polychon-
dritis, Cogan's syndrome, rheumatoid arthritis, Takayasu's
arteritis, and pemphigus).
Results
Of the 8,562 persons registered in the SITE database as of
June 11, 2008, 59 patients with ANCA-positive vasculitis
were identified. Previous publications originating from
centers that contributed to the database may have included
data from some of these patients. Three subjects were
excluded from the study due to discrepancies in dates
recorded in the database. Of the 56 individuals with
ANCA-positive vasculitis, 35 were male and 21 were
female. The majority of individuals were white (49 patients,
87.5%). Mean age at diagnosis was 48 years (range, 16–
96 years). The first recorded patient evaluation took place
on March 31, 1986, and the last recorded patient evaluation
took place on June 7, 2007. Mean duration of inflammatory
eye disease, from diagnosis through last visit to a SITE
study center, was 4.6 years (range, 0–26.3 years). Patient
characteristics are presented in Table 1.
Among the 56 individuals with the diagnosis of ANCA-
positive vasculitis, the distribution of ocular inflammatory
diagnoses was significantly different from that for the
remaining SITE population (p<0.001). There were 42
patients with scleritis (3.6% of 1,165 SITE cohort patients
identified as having scleritis), ten patients with uveitis
(0.13% of 7,239 SITE cohort patients identified as having
uveitis), and 19 patients with “other” ocular inflammatory
diagnoses (6.7% of 285 SITE cohort patients identified as
having inflammatory eye diseases other than scleritis or
uveitis). Non-necrotizing anterior scleritis was the most
common subtype of scleritis and was present in 27 patients
(64.3% of scleritis cases and 48.2% of all cases of ANCA-
positive vasculitis); of these 27 patients, 74.1% of individ-
uals had the diffuse form and 25.9% of individuals had the
nodular form. Necrotizing scleritis was diagnosed in 12
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ANCA-positive vasculitis). Two patients suffered from
concurrent anterior and posterior scleritis. Episcleritis was
uncommon, affecting just three patients. The majority of
cases of uveitis were classified as anterior (70% of
uveitis and 19.6% of all cases of ANCA-positive
vasculitis). Five patients suffered from both scleritis and
uveitis. The diagnostic category, “other”, included pe-
ripheral ulcerative keratitis (n=9), orbital pseudotumor
(n=6), and other conditions (n=4). Table 2 gives the ocular
diagnoses for all patients. Laterality, distribution of inflam-
mation, and temporal pattern of scleritis are presented in
Table 3.
During the period of study, oral corticosteroid therapy
was used by 48 patients (85.7%), and non-corticosteroid
systemic immunosuppressive agents were used by 44
patients (78.6%). Thirty patients (53.6%) were treated
with cyclophosphamide. A total of 15 cataract surgical
procedures were performed on nine patients, and 17
patients had a total of 24 various other ocular surgeries,
including dacryocystorhinostomy, and corneal or scleral
patching. Medical and surgical interventions for the 56
patients with ANCA-positive vasculitis are listed in
Tables 4 and 5.
The subset of the cohort seen by 2005 totaled 7,957
patients, including 56 with ANCA-positive vasculitis. Mor-
tality occurred at a rate of 0.040/person-year (95% CI, 0.22–
0.066) among patients with ANCA-positive vasculitis versus
0.014/person-year for the rest of the cohort (p<0.001; Fig. 1).
The risk of mortality was 2.75-fold higher among patients
with ANCA-positive vasculitis (95% CI, 1.49–5.06), after
adjusting for the confounding factors listed in the Methods
section. Figure 1 shows the Kaplan–Meier survival plot
demonstrating probability of survival over time for patients
with ANCA-positive vasculitis (n=56) versus patients with
all other diagnoses (n=7,901).
Diagnosis (principal or other) Number of patients, n=56 (%) Number of eyes, n=90 (%)
Scleritis 42 (75.0) 64 (71.1)
Episcleritis 3 (5.4) 5 (5.6)
Anterior Scleritis 27 (48.2) 43 (47.8)
a
Necrotizing Scleritis 12 (21.4) 16 (17.8)
Posterior Scleritis 2(3.6) 3 (3.3)
Uveitis 10 (17.9) 12 (13.3)
Anterior 7 (12.5) 8 (8.9)
a
Intermediate 1 (1.8) 1 (1.1)
Posterior or Panuveitis 2 (3.6) 3 (3.3)
Other Ocular Inflammatory Disease 19 (33.9) 27 (30.0)
Dacroadenitis 0 (0) 0 (0)
Orbital Myositis 0 (0) 0 (0)
Orbital Pseudotumor 6 (10.7) 11 (12.2)
Peripheral Ulcerative Keratitis 9 (16.1) 10 (11.1)
Other 4 (7.1) 6 (6.7)
Number of ocular diagnoses per
patient or eye
1 44 (78.6) 74 (82.2)
2 10 (17.9) 14 (15.6)
3 2 (3.6) 2 (3.6)
Table 2 Ocular diagnoses in
patients with ANCA-positive
vasculitis
aInformation is not recorded for
one patient
Table 1 Characteristics of patients with ANCA-positive vasculitis
Patient-specific variable Number of patients
(%) or mean ± SD
(range)
Gender
Male 35 (62.5)
Female 21 (37.5)
Race
White 49 (87.5)
Non-white 7 (12.5)
Age at diagnosis of inflammatory eye disease
(years)
48.2±16.4 (16–96)
Age at presentation to SITE center (years) 50.4±15.8 (17–97)
Duration of inflammatory eye disease at
presentation to SITE center (months)
26±54 (0–302)
Duration of follow-up at SITE center (months) 30±35 (0–129)
Duration of inflammatory eye disease (years) 4.6±5.7 (0–26.3)
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ANCA-positive vasculitis is multi-system inflammatory
disease that may affect different ocular tissues and/or the
orbit. Our study provides a comprehensive review of the
clinical aspects of this condition, as documented for 56
patients at five tertiary-referral inflammatory clinics across
the United States. Scleritis was the most common ocular
Subtype Clinical features Number of patients,
n=56 (%)
Number of eyes, n=90
(%)
Episcleritis Laterality
(n=3 patients) Unilateral 1 (1.8) 1 (1.1)
(n=5 eyes) Bilateral 2 (3.6) 4 (4.4)
Distribution
Diffuse 0 (0) 0 (0)
Nodular 1 (1.8) 1 (1.1)
Unknown 2 (3.6) 4 (4.4)
Temporal pattern
Single episode 0 (0) 0 (0)
Recurring 1 (1.8) 1 (1.1)
Chronic 1 (1.8) 2 (2.2)
Unknown 1 (1.8) 2 (2.2)
Anterior scleritis Laterality
(n=27 patients) Unilateral 10 (17.9) 9 (10.0)
(n=43 eyes)
a Bilateral 17 (30.4) 34 (37.8)
Unknown 0 (0) 0 (0)
Distribution
Diffuse 20 (35.7) 32 (35.6)
Nodular 7 (12.5) 11 (12.2)
Temporal pattern
Single episode 5 (8.9) 6 (6.7)
Recurring 11 (19.6) 17 (18.9)
Chronic 11 (19.6) 20 (22.2)
Necrotizing scleritis Laterality
(n=12 patients) Unilateral 8 (14.3) 8 (8.9)
(n=16 eyes) Bilateral 4 (7.1) 8 (8.9)
Unknown 0 (0) 0 (0)
Distribution
Focal 6 (10.7) 7 (7.8)
Widespread 3 (5.4) 4 (4.4)
Unknown 3 (5.4) 5 (5.6)
Temporal pattern
Single episode 2 (3.6) 2 (2.2)
Recurring 3 (5.4) 4 (4.4)
Chronic 5 (8.9) 7 (7.8)
Unknown 2 (3.6) 3 (3.3)
Posterior scleritis
b Laterality
(n=2 patients) Unilateral 1 (1.8) 1 (1.1)
(n=3 eyes) Bilateral 1 (1.8) 2 (2.2)
Temporal pattern
Single episode 0 (0) 0 (0)
Recurring 1 (1.8) 1 (1.1)
Chronic 1 (1.8) 2 (2.2)
Table 3 Characteristics of
scleritis in patients with ANCA-
positive vasculitis
aInformation is not recorded for
one patient
b Both patients with posterior
scleritis also had anterior scleritis
16 j ocul biol dis inform (2010) 3:12–19diagnosis in our patient cohort, accounting for 75% of the
inflammatory eye disease. Non-necrotizing anterior scleritis
was the most frequently observed subtype of scleritis, but
necrotizing disease affected approximately one quarter of
patients. Uveitis, peripheral ulcerative keratitis, and orbital
inflammation were other manifestations. Notably, although
an association between systemic and retinal vasculitis is
commonly assumed, the majority of cases of uveitis were
anterior in nature. Moreover, 50% of patients with uveitis
also suffered from scleritis, suggesting that uveitis may
have been secondary to the scleral inflammation. In many
patients, ANCA-positive vasculitis required aggressive
therapy. During the study, the majority of our patients were
treated with systemic corticosteroids, and over three-
quarters of the group were prescribed systemic immuno-
suppressive medications, including cyclophosphamide in
54% of cases. Patients with ANCA-positive vasculitis were
at 2.75-fold increased risk of death in comparison to other
patients with ocular inflammation.
Two single-center retrospective studies [10, 12] and one
review of published cases [15] have documented the ocular
and/or orbital involvement in patients with ANCA-positive
vasculitis. All three reports describe a diversity of manifes-
tations, including inflammations of the orbit and nasolacri-
mal system, conjunctiva, cornea, episclera, sclera, uvea, and
retina. Some of these manifestations, such as conjunctivitis
(12.5–25%) and nasolacrimal obstruction (up to 25%), were
not specifically assessed for the SITE cohort of patients.
With regard to the diagnoses that were recorded in the
database, these three reports found orbital inflammation to
be the most common manifestation (25–45%). Scleritis and
episcleritis, the most common group of ocular diagnoses in
our patients (75%), were also observed frequently (15–
38%). One likely explanation for the different distribution
of ocular diagnoses is that the cited reports included all
patients presenting to the institution or all patients described
in the literature of the day, respectively, whereas the clinical
information in the SITE database was collected from
tertiary-referral inflammatory eye disease clinics only. A
fourth single-center study involved 47 patients who were
managed at the Ocular Immunology Service of the
Massachusetts Eye and Ear Infirmary (MEEI) [21], which
is a tertiary-referral inflammatory eye disease clinic.
Interestingly, in that series, 74% of patients with ANCA-
positive vasculitis had scleritis, and in 67% of patients this
was necrotizing. Some of those patients are included in this
report. One notable conclusion from the MEEI-based study
was that eye involvement may be the first clinical evidence
of ANCA-positive vasculitis.
A comprehensive review of therapy for ANCA-positive
vasculitis, published in 2006 by White and Lynch [22],
provides recommendations for pharmacologic management.
A regimen of daily corticosteroid combined with cyclo-
phosphamide is the treatment of choice to induce remission
in patients with severe, life-threatening disease. The
Fig. 1 Kaplan–Meier survival plot demonstrating probability of
survival over time for 7,957 SITE cohort patients who were managed
on or before December 2005, and who were residents of the United
States. Patients with ANCA-positive vasculitis (n=56) are represented
by the dashed line. Patients with all other diagnoses (n=7,901) are
represented by the solid line
Table 4 Medical interventions in patients with ANCA-positive
vasculitis (n=56 patients)
Medical therapies Number of patients (%)
Oral corticosteroid 48 (85.7)
Methotrexate 19 (33.9)
Azathioprine 7 (12.5)
Mycophenolate mofetil 5 (8.9)
Leflunomide 1 (1.8)
Dapsone 1 (1.8)
Cyclosporin 2 (3.6)
Cyclophosphamide 30 (53.6)
Chlorambucil 3 (5.4)
Biologics 6 (10.7)
Table 5 Surgical interventions in patients with ANCA-positive
vasculitis (n=56 patients)
Surgical interventions
Cataract surgery 9 patients; 15 operations
Glaucoma surgery 0 patients; 0 operations
Other ocular surgery
(e.g., dacrocystorhinostomy,
scleral or corneal patch grafting,
ocular tissue biopsies)
17 patients; 24 operations
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per day and prednisone 1 mg/kg body weight per day was
tested by Hoffman et al. [5] in their prospective study
conducted at NIAID. Of 133 patients treated with this
therapy, 91% experienced improvement and 75% experi-
enced complete resolution of disease. In patients with
moderately severe disease, methotrexate or azathioprine
may be used to maintain remission [22]. Metzler et al. [23]
showed that leflunomide may be superior to methotrexate
in the prevention of major relapses. Biologics such as tumor
necrosis factor (TNF) antagonists and rituximab, an
antibody directed against CD20, have been studied on a
smaller scale [22]. Regardless of the chosen therapy,
relapses are not uncommon, and complications of treatment
can be severe. In one placebo-controlled trial of etanercept,
in addition to systemic glucocorticoids plus cyclophospha-
mide or methotrexate for maintenance of remission, there
was a striking difference in toxicity between the groups;
solid malignancies developed in six of the 89 patients in the
etanercept group but none of the 92 patients in the control
group [24].
While trials focusing on the treatment of systemic
manifestations of ANCA-positive vasculitis are often large,
controlled, clinical studies, reports of therapy for patients
with ocular and/or orbital manifestations are more limited
in terms of numbers of patients and level of evidence. In
1997, Perry et al. [25] published a series of 13 patients with
ANCA-positive vasculitis and orbital involvement. System-
ic corticosteroids alone were used in ten patients, but only
one of these patients experienced remission of disease.
Eventually, the majority of the ten patients were treated
with the combination of a systemic immunosuppressive
medication or trimethoprim–sulfamethoxazole and cortico-
steroid. A retrospective series of 29 Australian and New
Zealand patients with orbital and adnexal manifestations,
published in 2001, included 83% of patients who received
prednisone and 62% of patients who took cyclophospha-
mide [26]. Some subjects in this study were treated with
trimethoprim–sulfamethoxazole (24%) or radiotherapy
(17%). During the period of study, 86% of our population
was treated with oral corticosteroids. Forty-four patients
were treated with other systemic immunosuppressive
agents; 19 individuals (34%) used methotrexate, and 30
individuals (54%) used cyclophosphamide. Six of the 56
patients received biologic agents. The use of biologic
agents in our study alone probably reflects the fact that
our clinical data were collected through 2007, i.e.,
including the period of time when biologic agents have
become standard therapy for certain inflammatory diseases,
whereas other studies were conducted prior to that time.
Our study has certain limitations that warrant discussion.
Foremost are ascertainment bias and the retrospective
nature of the data collection. In addition, the SITE database
was constructed for the specific purpose of identifying
incidence of malignancy in patients receiving systemic
immunosuppressive medications for inflammatory eye
disease. For this reason, some disease- and treatment-
related data were limited in relation to the subject of our
investigation. In particular, the clinical or laboratory criteria
used to make the diagnosis of ANCA-positive vasculitis
were not recorded in the database. Authors of smaller
studies have specified their use of clinical features, ANCA
positivity, and/or tissue biopsies demonstrating granuloma-
tous inflammation with vasculitis and necrosis [11, 13, 21,
25, 26]. For our multi-centered review, we had to assume
that the diagnosis was made appropriately by SITE
clinicians, all of whom were academic uveitis specialists
and expected to confirm a diagnosis of ANCA-positive
vasculitis according to standard criteria, such as the 1990
American College of Rheumatology Criteria for Wege-
ner's granulomatosis [27]. Finally, while some investiga-
tors have reported results of medical and surgical therapies
by following clinical improvements and remission of
different manifestations of ANCA-positive vasculitis
[5, 11, 14, 25], our methods did not allow us to track the
effectiveness of therapy in specific instances. The sam-
pling procedure conducted at one institution is unlikely to
impact our results because patients with ANCA-positive
vasculitis are one subgroup that is likely to receive
systemic immunosuppression.
Despite the discussed limitations, our description of the
ocular manifestations of ANCA-positive vasculitis involves
a relatively large group of patients who have been managed
at multiple centers. In presenting data from five major
tertiary-referral inflammatory eye disease clinics in the
United States, our study provides a broad representation of
ANCA-positive vasculitis. We observed that ANCA-
positive vasculitis involved different ocular tissues and the
orbit, but most commonly was manifested as scleritis.
Patients with ocular complications of ANCA-positive
vasculitis were at increased risk of mortality, despite the
frequent systemic use of corticosteroid and immunosup-
pressive medications.
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